Napredna pretraga

Pregled bibliografske jedinice broj: 695005

Ca 19-9: Is there a role for potential new biomarker for medullary thyroid cancer?

Katalinic, Darko; Santek, Fedor; Juretic, Antonio; Stern-Padovan, Ranka; Nikolac, Nora; Grah, Josip Joachim; Plestina, Stjepko
Ca 19-9: Is there a role for potential new biomarker for medullary thyroid cancer? // Endocrine Abstracts
Wrocław, Poland: Bioscientifica, 2014. (poster, međunarodna recenzija, sažetak, znanstveni)

Ca 19-9: Is there a role for potential new biomarker for medullary thyroid cancer?

Katalinic, Darko ; Santek, Fedor ; Juretic, Antonio ; Stern-Padovan, Ranka ; Nikolac, Nora ; Grah, Josip Joachim ; Plestina, Stjepko

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Endocrine Abstracts / - Wrocław, Poland : Bioscientifica, 2014

16th European Congress of Endocrinology

Mjesto i datum
Wrocław, Poland, 03-07.05.2014

Vrsta sudjelovanja

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Ca 19-9; medullary thyroid cancer

In the recent years, knowledge about cancer biomarkers has increased tremendously providing great opportunities for improving the diagnosis, prognosis and treatment of cancer patients. In clinical practice, the levels of serum calcitonin, and carcinoembryonic antigen (CEA) are important during follow-up for patients with medullary thyroid cancer (MTC). Carbohydrate antigen 19-9 (CA 19-9), routinely used in the monitoring of pancreatic, hepatobiliary, and colon carcinoma, also has been detected in the tissue of - 6% of MTCs. However, its presence has never been reported in the serum of these patients. We report seven cases of MTC presenting with elevated CA 19-9 serum levels (average level: 145 IU/l and normal range: <37 IU/l). All patients were Caucasians of European origin, (two males and five females ; age range: 45–67 years), without any clinical findings of gastrointestinal cancer or inflammation. Additionally, the immunostaining of the MTC tissue showed positive result for calcitonin and CEA and strongly positive staining for CA 19-9. The future of cancer management lie in the use of biomarkers that offer the potential to identify the cancer years before it is either visible or symptomatic. Exploring the presence of these markers that does not require the tumour tissue to detect them, but are secreted by cancer cells into the blood stream will not only facilitate easy detection, but will also be candidates for population based screening. A comprehensive understanding of the relevance of each biomarker will be important to efficiently diagnose the disease and provide appropriate strategies in the multiple therapeutic alternatives currently available that are likely to benefit to the cancer patients.

Izvorni jezik

Znanstvena područja
Biologija, Temeljne medicinske znanosti, Kliničke medicinske znanosti


Projekt / tema
108-1080058-0047 - Molekularni biljezi u solidnim tumorima - prediktivni i prognostički značaj (Stjepko Pleština, )

Medicinski fakultet, Zagreb